Literature DB >> 26077346

VEGF gene transfected umbilical cord mesenchymal stem cells transplantation improve the lower limb vascular lesions of diabetic rats.

Xiaoling Li1, Kexin Gan2, Guangyao Song3, Chao Wang2.   

Abstract

BACKGROUND: Previous studies had explored the therapeutic effect of hUC-MSCs transplantation on ischemia; in this study, we further assessed the effectiveness of VEGF over-expressed hUC-MSCs cells transplantation on vascular proliferation in lower limb ischemia model in type 2 diabetic rats.
METHODS: hUC-MSCs cells were over-expressed with VEGF, and transplanted to lower limb ischemia rats model of type 2 diabetes.
RESULTS: VEGF over-expression increased the hUC-MSCs cells proliferation activity and VEGF secretion. VEGF gene transfected hUC-MSCs transplantation increased VEGF expression at a high level throughout 4weeks in skeletal muscle tissues of rats. Importantly, the vascular proliferation and blood perfusion of VEGF over-expressed hUC-MSCs transplanted limb were significantly improved compared with those of control group. The expression levels of ERK, AKT, MMP2 and MMP9 in VEGF over-expressed hUC-MSCs transplantation group increased dramatically compared with control group, while TIMP1 and TIMP2 expression had no significant change.
CONCLUSION: VEGF over-expressed hUC-MSCs transplantation was more effective to stimulate angiogenesis and increase blood perfusion than the simply hUC-MSCs transplantation, as maybe a new choice to improve the lower limb vascular lesions of diabetics.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Lower limb vascular lesion; Stem cells; Transplantation; VEGF

Mesh:

Substances:

Year:  2015        PMID: 26077346     DOI: 10.1016/j.jdiacomp.2015.04.018

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

1.  Hypoxia pretreatment improves the therapeutic potential of bone marrow mesenchymal stem cells in hindlimb ischemia via upregulation of NRG-1.

Authors:  Xitao Peng; Bing Liang; Haisheng Wang; Jingyuan Hou; Qidong Yuan
Journal:  Cell Tissue Res       Date:  2022-01-29       Impact factor: 5.249

2.  Erythropoietin Modification Enhances the Protection of Mesenchymal Stem Cells on Diabetic Rat-Derived Schwann Cells: Implications for Diabetic Neuropathy.

Authors:  Shuyun Zhang; Baolin Shi
Journal:  Biomed Res Int       Date:  2017-02-19       Impact factor: 3.411

3.  Muscle Derived Stem Cells Stimulate Muscle Myofiber Repair and Counteract Fat Infiltration in a Diabetic Mouse Model of Critical Limb Ischemia.

Authors:  J Tsao; I Kovanecz; N Awadalla; R Gelfand; I Sinha-Hikim; R A White; N F Gonzalez-Cadavid
Journal:  J Stem Cell Res Ther       Date:  2016-12-26

4.  IGF-1C domain-modified hydrogel enhances therapeutic potential of mesenchymal stem cells for hindlimb ischemia.

Authors:  Nianhuan Zhao; Zhiwei Yue; Jian Cui; Yong Yao; Xianghe Song; Bangping Cui; Xin Qi; Zhibo Han; Zhong-Chao Han; Zhikun Guo; Zuo-Xiang He; Zongjin Li
Journal:  Stem Cell Res Ther       Date:  2019-04-29       Impact factor: 6.832

5.  Hydrogen sulfide improves vessel formation of the ischemic adductor muscle and wound healing in diabetic db/db mice.

Authors:  Guo-Guang Wang; Wei Li
Journal:  Iran J Basic Med Sci       Date:  2019-10       Impact factor: 2.699

6.  Fibroblast Growth Factor 1 Gene-Transfected Adipose-Derived Mesenchymal Stem Cells Modulate Apoptosis And Inflammation In The Chronic Constriction Injury Model of Neuropathic Pain.

Authors:  Fatemeh Forouzanfar; Hamid R Sadeghnia; Seyed Javad Hoseini; Ahmad Ghorbani; Hamed Ghazavi; Faezeh Ghasemi; Hossein Hosseinzadeh
Journal:  Iran J Pharm Res       Date:  2020       Impact factor: 1.696

7.  Recombinant fusion protein by lysozyme and antibacterial peptide enhances ischemic wound healing via angiogenesis and reduction of inflammation in diabetic db/db mice.

Authors:  Wei Li; Yu-Xin Jiang; Qing-Ying Chen; Guo-Guang Wang
Journal:  PeerJ       Date:  2021-04-16       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.